<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Selenium-binding protein 1 is down-regulated in malignant melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Selenium-binding protein 1 is down-regulated in malignant melanoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53e7/5828193/50814050863b/oncotarget-09-10445-g003.jpg"/> </div> <div class="text-side"> <h1>Selenium-binding protein 1 is down-regulated in malignant melanoma.</h1> <p>SELENBP1 in vivo in human melanoma (patient)(A) Expression analysis of SELENBP1 in nevi, melanocytes and keratinocytes. (B) Tissue of normal skin (n = 4), primary melanoma (n = 4) and melanoma metastasis (n = 4) were analyzed for SELENBP1 expression on mRNA level. (C) Geoprofile data sets (GDS1375) showed SELENPB1 mRNA expression in normal skin (NS) and in primary tumor (PT) and metastasis (MET) of melanoma patient. (D) SELENBP1 protein level was analyzed by Western blot analysis. Values below the blot indicate the ratio between SELENBP1 and GAPDH for each sample and were calculated using ImageJ. (E) Immunohistochemical analysis showed SELENBP1 staining in primary melanoma biopsies (n = 5) and melanoma metastases (n = 5) compared to nevi tissue (n = 6). Representative microscopy images were shown for each tissue, as well as H&amp;E staining. (F) Statistical analysis of SELENBP1 immunohistochemistry. Evaluation was performed by a classification into three categories: low, moderate and high SELENBP1 protein expression.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29535818/" target="_blank">29535818</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>